# NCT03042468 (NCT03042468)

> Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03042468
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Weill Medical College of Cornell University
- Conditions: Prostate Cancer
- Interventions: 177Lu-PSMA-617; 68Ga-PSMA-HBED-CC
- Enrollment: 50
- Primary outcome: Number of Subjects With Dose Limiting Toxicity (DLT) of Fractionated Dose of 177Lu-PSMA-617
- Primary outcome: Number of Subjects That Achieved Cumulative Maximum Tolerated Dose (MTD) Phase II Dose of 177Lu-PSMA-617
- Primary outcome: Recommended Phase II Dose of 177Lu-PSMA-617 in a 2-week Dose-fractionation Regimen

## Indexed commentary on NCT03042468 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03042468